Intrathecal Pemetrexed

How it works

Dosage & preparation

Evidence quality

Highlighted claims

• Cohort A receives intrathecal pemetrexed 50 mg twice in the first week and then once every 4 weeks. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• Cohort B uses intrathecal pemetrexed 50 mg with intrathecal bevacizumab. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• Intrathecal chemotherapy delivers drugs directly into the subarachnoid space and can produce higher local drug concentrations at the disease site. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• There are no standardised guidelines defining the optimal intrathecal pemetrexed dose or frequency for NSCLC leptomeningeal metastases. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• Prior NSCLC leptomeningeal metastasis studies have shown safety signals, symptom improvement, and survival benefit for intrathecal pemetrexed, but resistance remains a major problem. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial